Global Typhoid Fever Vaccines Market
, by Vaccine Type (Live Attenuated Vaccine, Capsular Polysaccharide Vaccines, Conjugate Vaccine, and Others), by Typhoid Fever Vaccines Type (Oral and Parental), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
was valued at US$ 225.0 Mn
in 2018, and is projected to exhibit a CAGR of 11.9%
during the forecast period (2018–2026), as highlighted in a new report published by .
Increasing government initiatives for rising awareness regarding typhoid vaccines and supporting access to new vaccines are expected to support the global typhoid fever vaccines market growth.
Active involvement by organizations such as GAVI Alliance (Global Alliance for Vaccines and Immunisation), UNICEF (The United Nations International Children's Emergency Fund), WHO (World Health Orginization), and others in increasing accessibility of these vaccines in emerging economies is further expected to fuel typhoid fever vaccines market growth.
For instance, in April 2018, Gavi designated US$ 85 million to fund introduction of Typbar TCV (Bharat Biotech) vaccine in low-income countries across Africa and Asia region. Moreover, there are several typhoid conjugate vaccines present in the pipeline, which are expected to enter in the market over the forecast period.
In October 2017, WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) re-emphasized the importance of typhoid vaccines in low- and middle-income countries, as well as for the control of endemic typhoid.
Moreover, the Typhoid Vaccine Acceleration Consortium (TyVAC), which is a partnership between University of Maryland School of Medicine, University of Oxford and PATH, is currently conducting clinical trials for Typbar TCV prequalified vaccine in Malawi, Nepal, and Bangladesh to further evaluate clinical efficacy and potential of the vaccine in reducing typhoid burden in these countries.
Furthermore, introduction of clinically more effective typhoid vaccines in private markets (such as India) as well as internationally has supported growth of the market. For instance, Vivotif (oral vaccine), clinically more effective Typhim Vi (WHO prequalified in 2011), and now Typbar TCV (first conjugate vaccine WHO prequalified in 2017) are now available in the market
Browse 26 Market Data Tables and 25 Figures spread through 177 Pages and in-depth TOC on Global Typhoid Fever Vaccines Market By Vaccine Type (Live Attenuated Vaccine, Capsular Polysaccharide Vaccines, Conjugate Vaccine, and Others), by Typhoid Fever Vaccines Type (Oral and Parental), and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Global Forecast to 2026
To know the latest trends and insights prevalent in the Typhoid Fever Vaccines market, click the link below:
Efficient antibiotic treatment can reduce the fatality rate of typhoid to less than 1%. However, recent past has witnessed an increase in antimicrobial resistance of Salmonella Typhi.
For instance, according to the Typhoid Vaccine Acceleration Consortium (TyVAC), which is a partnership between University of Maryland School of Medicine, University of Oxford and PATH, by 2014, 97% of registered typhoid cases in Malawi have resisted treatment from multiple antibiotics.
As per the same source, the antibiotic resistant typhoid cases are increasing globally. In relation to this, in 2015, the World Health Assembly (WHA) started a global action plan to tackle drug resistance, which focuses on prevention, surveillance, and research of antibiotic resistance.
Moreover, the Wellcome Trust and current surveillance projects, including Surveillance for Enteric Fever in Asia Project (SEAP) and Severe Typhoid Fever Surveillance in Africa (SETA) are conducting research to identify typhoid drug-resistance trends and monitor antibiotic use across South Asia and sub-Saharan Africa
This is expected to shift the attention towards diseases prevention rather than cure, which in turn will have positive impact on increasing immunization efforts. This, along with all the other drivers (disease prevalence, increasing government support, initiatives, and product launches) is expected to support growth of the market over the forecast period
Key Takeaways of the Typhoid Fever Vaccines Market:
- The global typhoid fever vaccines market is expected to exhibit a CAGR of 11.9% during the forecast period (2018 – 2026), owing to frequent product launches and approvals, and robust pipeline of novel typhoid fever vaccines
- Asia Pacific typhoid fever vaccines market is expected to account for largest market share, owing to high prevalence of typhoid fever. For instance, according to the data published by Medindia around 18,45,997 cases of typhoid were found in India in 2015
- North America typhoid fever vaccines market is expected to show stagnant growth over the forecast period, owing to low prevalence of typhoid in region. For instance, according to the data published by Centers of Disease Control and Prevention (CDC) 2017, around 300 culture-confirmed cases of typhoid fever and 80 cases of paratyphoid fever caused by S. enterica serotype Paratyphi A are reported annually in the U.S.
- Major players operating in the typhoid fever vaccines market include GlaxoSmithKline Plc., Sanofi SA, Bharat Biotech, Bio-Med Pvt. Ltd., PT Bio Farma, PaxVax, Inc. Shanghai Institute of Biological Products Co., Ltd., and Prokarium